-
Mashup Score: 7Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer - 2 month(s) ago
PURPOSE Circulating carbohydrate antigen 19-9 (CA19-9) levels reflect FUT3 and FUT2 fucosyltransferase activity. Measuring the related glycan, DUPAN-2, can be useful in individuals unable to synthesize CA19-9. We hypothesized that similar to CA19-9, FUT functional groups determined by variants in FUT3 and FUT2 influence DUPAN-2 levels, and having tumor marker reference ranges for each functional group would improve diagnostic performance. MATERIALS AND METHODS Using a training/validation study design, FUT2/FUT3 genotypes were determined in 938 individuals from Johns Hopkins Hospital: 607 Cancer of the Pancreas Screening (CAPS) study subjects with unremarkable pancreata and 331 with pancreatic ductal adenocarcinoma (PDAC). Serum DUPAN-2 and CA19-9 levels were measured by immunoassay. RESULTS In controls, three functional FUT groups were identified with significant differences in DUPAN-2 levels: FUT3-intact, FUT3-null/FUT2-intact, and FUT3-null/FUT2-null. DUPAN-2 training set diagnostic
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study - 2 month(s) ago
PURPOSE Previous studies suggest that besides anatomy (A: resectable, borderline resectable [BR], or locally advanced [LA]) also biologic (B: carbohydrate antigen 19-9 [CA 19-9]) and conditional (C: performance status) factors should be considered when staging patients with localized pancreatic ductal adenocarcinoma (PDAC). The prognostic value of the combined ABC factors has not been quantitatively validated. METHODS In this retrospective cohort study, we evaluated patients with localized PDAC treated with initial (modified) fluorouracil with leucovorin, irinotecan, and oxaliplatin ([m]FOLFIRINOX) at five high-volume pancreatic cancer centers in the United States and the Netherlands (2012-2019). Multivariable Cox proportional hazards analysis was used to investigate the impact of the ABC factors for overall survival (OS). RESULTS Overall, 1,835 patients with localized PDAC were included. Tumor stage at diagnosis was potentially resectable in 346 (18.9%), BR in 531 (28.9%), and LA in 9
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9Stage Classification and Prognosis Assessment in Localized Pancreatic Cancer: It Takes Two to Tango - 3 month(s) ago
Although the 5-year survival of patients diagnosed with localized pancreatic ductal adenocarcinoma (PDAC) has increased from 32% to 44% over the 2018-2023 period, 1, 2 predicting the probability of cure and selecting the optimal therapeutic strategy in individual patients remains extremely difficult. Anatomical disease extent, especially regarding vascular involvement, is mostly perceived as a technical challenge for the surgeo n to achieve a R0 resection; similarly, patient’s performance status (PS) and
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 05 Nutritional Screening Tools Best at Predicting Prognosis in Pancreatic Cancer - Oncology Nurse Advisor - 3 month(s) ago
A meta-analysis of 27 studies sought to determine which malnutrition assessment tools best predicted prognosis for patients with pancreatic cancer.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations - 5 month(s) ago
PURPOSE We evaluated the potential cost-effectiveness of combined magnetic resonance imaging (MRI) and endoscopic ultrasound (EUS) screening for pancreatic ductal adenocarcinoma (PDAC) among populations at high risk for the disease. METHODS We used a microsimulation model of the natural history of PDAC to estimate the lifetime health benefits, costs, and cost-effectiveness of PDAC screening among populations with specific genetic risk factors for PDAC, including BRCA1 and BRCA2, PALB2, ATM, Lynch syndrome, TP53, CDKN2A, and STK11. For each high-risk population, we simulated 29 screening strategies, defined by starting age and frequency. Screening included MRI with follow-up EUS in a subset of patients. Costs of tests were based on Medicare reimbursement for MRI, EUS, fine-needle aspiration biopsy, and pancreatectomy. Cancer-related cost by stage of disease and phase of treatment was based on the literature. For each high-risk population, we performed an incremental cost-effectiveness a
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
🔬 Staged MRI/EUS screening can be cost-effective for populations at highest risk for #PancreaticCancer #pancsm. However, screening was only cost-effective for pop at moderate risk in men at higher WTP thresholds ($200K/QALY) & with 1-time screening. ➡️ https://t.co/pr28y977JX https://t.co/Rvs1jkXQ6A
-
🌟 A tumor marker gene test improves blood test (CA19-9, DUPAN-2) accuracy for early #PancreaticCancer: https://t.co/qs8lgWMOqj @mggoggins #PancSM https://t.co/rOxIQYcsCQ